SAIC Announces Fourth Quarter and Full Fiscal Year 2026 Results
Rhea-AI Summary
SAIC (NASDAQ: SAIC) reported Q4 FY26 revenue of $1.75B and full-year revenue of $7.26B. Q4 net income was $85M and FY26 net income was $358M. Adjusted EBITDA was $181M (10.3%) for Q4 and $708M (9.7%) for FY26. Adjusted diluted EPS was $10.75 for FY26. Cash flow from operations was $609M for FY26 and free cash flow $577M. SAIC provided FY27 guidance: revenue $7.0B–$7.2B, adjusted EBITDA $705M–$715M, adjusted diluted EPS $9.50–$9.70, and free cash flow >$600M.
Positive
- Adjusted diluted EPS +18% YoY to $10.75
- Adjusted EBITDA of $708M for FY26 (9.7% margin)
- FY26 free cash flow of $577M and operating cash flow $609M
- Share repurchases of $422M in FY26 (≈4.0M shares)
Negative
- Revenue down 3% YoY to $7.26B
- Q4 net bookings only $0.6B with book-to-bill of 0.3
- FY27 organic growth guide of (4%)–(2%) implies continued contraction
News Market Reaction – SAIC
On the day this news was published, SAIC declined 1.27%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SAIC was up 0.4% pre‑release. Peers showed mixed action: APLD up modestly on momentum scans, while several high‑affinity peers (e.g., PSN, VRRM) were down earlier in the session, pointing to stock‑specific drivers rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Prelim FY26 update | Negative | -16.0% | Preliminary FY26 results with lowered FY27 revenue outlook despite stronger margins. |
| Dec 04 | Q3 FY26 earnings | Positive | +16.3% | Q3 beat on profitability, strong bookings and guidance raise drove a positive reaction. |
| Sep 04 | Q2 FY26 earnings | Negative | -6.9% | Q2 revenue decline and lowered FY26 revenue guidance outweighed solid margins and wins. |
| Jun 02 | Q1 FY26 earnings | Neutral | -13.3% | Mixed Q1 with revenue growth but lower net income and reaffirmed guidance. |
| Mar 17 | FY25 earnings | Positive | +7.2% | Strong FY25 revenue growth, solid margins and sizable backlog supported a gain. |
Across the last five earnings‑tagged releases, SAIC’s stock often reacted sharply, with an average move of about -2.55%, skewed by a -16.03% drop on the February 2026 preliminary FY26 update.
Recent earnings and related updates show a shift from FY2025 growth to FY2026 top‑line pressure but improving margins and cash generation. Earlier FY2026 quarters featured lowered revenue guidance alongside stronger profitability, culminating in the Feb 11, 2026 preliminary FY26 results and reduced FY27 revenue outlook (news_id 1011341). That update triggered a -16.03% move, framing today’s finalized FY26 figures and reiterated FY27 guidance as part of an ongoing recalibration rather than a new strategic turn.
Historical Comparison
In the past five earnings releases, SAIC’s average move was -2.55%, with reactions ranging from a -16.03% selloff on the FY26 prelim update to a 16.29% jump on Q3 FY26 results, underscoring historically high sensitivity to earnings quality and guidance shifts.
Earnings updates show FY2025 growth giving way to FY2026 revenue pressure, while adjusted EBITDA margins and free cash flow improved. Guidance now emphasizes flat‑to‑down FY2027 revenue at $7.0–$7.2B but higher 9.9%–10.1% adjusted EBITDA margins and >$600M free cash flow.
Market Pulse Summary
This announcement finalizes Q4 and FY2026 results showing softer revenue but stronger margins and cash flow, alongside FY2027 guidance for $7.0–$7.2B revenue, adjusted EBITDA of $705M–$715M, and adjusted EPS of $9.50–$9.70. Prior earnings updates in FY2026 repeatedly highlighted this tradeoff between top‑line pressure and profitability. Key factors to monitor include net bookings, book‑to‑bill ratio, backlog of $22.6B, and management’s ability to sustain >$600M in free cash flow while navigating organic revenue decline.
Key Terms
adjusted EBITDA financial
free cash flow financial
book-to-bill ratio financial
backlog financial
non-GAAP financial
Master Accounts Receivable Purchase Agreement financial
forward-looking statements regulatory
AI-generated analysis. Not financial advice.
- Q4 FY26 revenues of
$1.75 billion ; FY26 revenues of$7.26 billion - Q4 FY26 net income of
$85 million , adjusted EBITDA(1) of$181 million or10.3% of revenue; FY26 net income of$358 million , adjusted EBITDA(1) of$708 million or9.7% of revenue - Q4 FY26 diluted earnings per share of
$1.87 , adjusted diluted earnings per share(1) of$2.62 ; FY26 diluted earnings per share of$7.70 , adjusted diluted earnings per share(1) of$10.75 - Q4 FY26 cash flows provided by operating activities of
$258 million , free cash flow(1) of$336 million ; FY26 cash flows provided by operating activities of$609 million , free cash flow(1) of$577 million - Q4 FY26 net bookings of
$0.6 billion ; book-to-bill ratio of 0.3; trailing twelve months book-to-bill ratio of 1.1 - Announces FY27 guidance for adjusted diluted earnings per share(1) and reiterates revenue, adjusted EBITDA(1), adjusted EBITDA margin(1), and free cash flow(1) guidance
RESTON, Va., March 16, 2026 (GLOBE NEWSWIRE) -- Science Applications International Corporation (NASDAQ: SAIC), a premier Fortune 500 technology integrator driving our nation's digital transformation across the defense, space, civilian, and intelligence markets, today announced results for the fourth quarter and full fiscal year ended January 30, 2026.
"As previously announced on February 11, our fourth-quarter results reflected ongoing top-line challenges, balanced by strong operational execution that supports our ability to raise margin expectations moving forward," said Jim Reagan, SAIC’s Chief Executive Officer. "I am encouraged by the progress we are making and by the opportunities in front of us. Our plan is simple – we will focus on elements within our control to drive more consistent and reliable growth. With a career dedicated to operational excellence and value creation in our industry, I am honored to continue, as permanent CEO, building on SAIC’s solid foundation to deliver meaningful results to all stakeholders."
Fourth Quarter and Full Fiscal Year 2026: Summary Operating Results
| Three Months Ended | Year Ended | |||||||||||||||||||||
| January 30, 2026 | Percent change | January 31, 2025 | January 30, 2026 | Percent change | January 31, 2025 | |||||||||||||||||
| (dollars in millions, except per share amounts) | ||||||||||||||||||||||
| Revenues | $ | 1,750 | (5)% | $ | 1,838 | $ | 7,262 | (3)% | $ | 7,479 | ||||||||||||
| Operating income | 133 | (4)% | 138 | 521 | (7)% | 563 | ||||||||||||||||
| Operating income as a percentage of revenues | 7.6 | % | 10bps | 7.5 | % | 7.2 | % | -30bps | 7.5 | % | ||||||||||||
| Adjusted operating income(1) | 179 | 2 | % | 176 | 702 | — | % | 705 | ||||||||||||||
| Adjusted operating income as a percentage of revenues | 10.2 | % | 60bps | 9.6 | % | 9.7 | % | 30bps | 9.4 | % | ||||||||||||
| Net income | 85 | (13)% | 98 | 358 | (1)% | 362 | ||||||||||||||||
| EBITDA(1) | 175 | — | % | 175 | 676 | (5)% | 708 | |||||||||||||||
| EBITDA as a percentage of revenues | 10.0 | % | 50bps | 9.5 | % | 9.3 | % | -20bps | 9.5 | % | ||||||||||||
| Adjusted EBITDA(1) | 181 | 2 | % | 177 | 708 | — | % | 710 | ||||||||||||||
| Adjusted EBITDA as a percentage of revenues | 10.3 | % | 70bps | 9.6 | % | 9.7 | % | 20bps | 9.5 | % | ||||||||||||
| Diluted earnings per share | $ | 1.87 | (7)% | $ | 2.00 | $ | 7.70 | 7 | % | $ | 7.17 | |||||||||||
| Adjusted diluted earnings per share(1) | $ | 2.62 | 2 | % | $ | 2.57 | $ | 10.75 | 18 | % | $ | 9.13 | ||||||||||
| Net cash provided by operating activities | $ | 258 | 124 | % | $ | 115 | $ | 609 | 23 | % | $ | 494 | ||||||||||
| Free cash flow(1) | $ | 336 | 42 | % | $ | 236 | $ | 577 | 16 | % | $ | 499 | ||||||||||
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Fourth Quarter Summary Results
Revenues for the quarter decreased
Operating income as a percentage of revenues increased to
Adjusted EBITDA(1) as a percentage of revenues for the quarter was
Diluted earnings per share for the quarter was
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Fiscal Year 2026 Summary Results
Revenues for the fiscal year decreased
Operating income as a percentage of revenues for the fiscal year decreased compared to the prior year primarily due to executive transition costs, net of recoveries, the favorable resolution of the Assault Amphibious Vehicle ("AAV") contract termination in the prior year (
Adjusted EBITDA(1) as a percentage of revenues for the fiscal year increased compared to the prior year primarily due to a recovery of costs from the settlement of a patent infringement matter and lower other selling, general and administrative expenses, partially offset by the favorable resolution of the AAV contract termination in the prior year (
Diluted earnings per share for the year was
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Cash Generation and Capital Deployment
Total cash flows provided by operating activities for the fourth quarter were
Total cash flows provided by operating activities for the year were
During the quarter, SAIC deployed
Quarterly Dividend Declared
As previously announced, subsequent to fiscal year-end, the Company’s Board of Directors ("Board of Directors") declared a cash dividend of
Backlog and Contract Awards
Net bookings for the quarter were approximately
SAIC’s estimated backlog at the end of fiscal 2026 was approximately
SAIC was awarded the following notable contracts during the quarter:
Notable Space and Intelligence Community Awards:
U.S. Space and Intelligence Community: During the quarter, SAIC was awarded approximately
Notable New Awards:
U.S. Government Accountability Office ("GAO"): SAIC was awarded a new
Notable Awards Subsequent to Period End (not included in current quarter bookings):
U.S. Space and Intelligence Community: Subsequent to the end of the quarter, SAIC was awarded a seven-year recompete contract of approximately
Federal Civilian Community: Subsequent to the end of the quarter, SAIC was awarded a five-year (one-year base, plus four, one-year option periods) recompete contract of approximately
Fiscal Year 2027 Guidance
The Company's outlook for fiscal year 2027 is being provided, announcing guidance for adjusted diluted EPS(1) and reiterating the previously announced guidance for revenue, adjusted EBITDA(1), adjusted EBITDA margin(1), and free cash flow(1). The table below summarizes fiscal year 2027 guidance and represents our views as of March 16, 2026.
| CURRENT Fiscal Year | |
| 2027 Guidance | |
| Revenue | |
| Organic Growth | ( |
| Adjusted EBITDA(1) | |
| Adjusted EBITDA Margin %(1) | |
| Adjusted Diluted EPS(1) | |
| Free Cash Flow(1) | > |
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Webcast Information
SAIC management will discuss operations and financial results in an earnings conference call beginning at 10 a.m. Eastern time on March 16, 2026. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the SAIC website (http://investors.saic.com). We will be providing webcast access only – “dial-in” access is no longer available. Additionally, a supplemental presentation will be available to the public through links to the Investor Relations section of the SAIC website. After the call concludes, an on-demand audio replay of the webcast can be accessed on the Investor Relations website.
About SAIC
SAIC® is a premier Fortune 500 mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.
We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately
Media Contact
Darryn James
Director, Media and Brand Reputation
publicrelations@saic.com
Investor Relations Contact
Jon Raviv
Vice President, Investor Relations
investorrelations@saic.com
GAAP to Non-GAAP Guidance Reconciliation
The Company does not provide a reconciliation of forward-looking adjusted diluted EPS to GAAP diluted EPS or adjusted EBITDA margin to GAAP net income due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate net income may vary significantly based on actual events, the Company is not able to forecast GAAP diluted EPS or GAAP net income with reasonable certainty. The variability of the above charges may have an unpredictable and potentially significant impact on our future GAAP financial results.
Forward-Looking Statements
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at www.saic.com or on the SEC’s website at www.sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.
Schedule 1:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED AND CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| January 30, 2026 | January 31, 2025 | January 30, 2026 | January 31, 2025 | |||||||||||||
| (in millions, except per share amounts) | ||||||||||||||||
| Revenues | $ | 1,750 | $ | 1,838 | $ | 7,262 | $ | 7,479 | ||||||||
| Cost of revenues | 1,529 | 1,606 | 6,390 | 6,587 | ||||||||||||
| Selling, general and administrative expenses | 85 | 94 | 350 | 339 | ||||||||||||
| Other operating (income) expense | 3 | — | 1 | (10 | ) | |||||||||||
| Operating income | 133 | 138 | 521 | 563 | ||||||||||||
| Interest expense, net | 34 | 29 | 128 | 126 | ||||||||||||
| Other (income) expense, net | — | 2 | 6 | 9 | ||||||||||||
| Income before income taxes | 99 | 107 | 387 | 428 | ||||||||||||
| Provision for income taxes | (14 | ) | (9 | ) | (29 | ) | (66 | ) | ||||||||
| Net income | $ | 85 | $ | 98 | $ | 358 | $ | 362 | ||||||||
| Weighted-average number of shares outstanding: | ||||||||||||||||
| Basic | 45.0 | 48.6 | 46.3 | 50.1 | ||||||||||||
| Diluted | 45.4 | 49.0 | 46.5 | 50.5 | ||||||||||||
| Earnings per share: | ||||||||||||||||
| Basic | $ | 1.89 | $ | 2.02 | $ | 7.73 | $ | 7.23 | ||||||||
| Diluted | $ | 1.87 | $ | 2.00 | $ | 7.70 | $ | 7.17 | ||||||||
Schedule 2:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED AND CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||
| January 30, 2026 | January 31, 2025 | ||||
| (in millions) | |||||
| ASSETS | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 182 | $ | 56 | |
| Receivables, net | 853 | 1,000 | |||
| Prepaid expenses | 122 | 78 | |||
| Other current assets | 22 | 20 | |||
| Total current assets | 1,179 | 1,154 | |||
| Goodwill | 2,944 | 2,851 | |||
| Intangible assets, net | 761 | 779 | |||
| Property, plant, and equipment, net | 110 | 104 | |||
| Operating lease right of use assets | 193 | 164 | |||
| Other assets | 167 | 194 | |||
| Total assets | $ | 5,354 | $ | 5,246 | |
| LIABILITIES AND EQUITY | |||||
| Current liabilities: | |||||
| Accounts payable | $ | 500 | $ | 631 | |
| Accrued payroll and other employee benefits | 201 | 219 | |||
| Accrued vacation | 115 | 120 | |||
| Other accrued liabilities | 147 | 113 | |||
| Debt, current portion | 19 | 313 | |||
| Total current liabilities | 982 | 1,396 | |||
| Debt, net of current portion | 2,468 | 1,907 | |||
| Operating lease liabilities | 198 | 173 | |||
| Deferred income taxes | 104 | 24 | |||
| Other long-term liabilities | 102 | 169 | |||
| Equity: | |||||
| Total stockholders' equity | 1,500 | 1,577 | |||
| Total liabilities and stockholders' equity | $ | 5,354 | $ | 5,246 | |
Schedule 3:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED AND CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||
| January 30, 2026 | January 31, 2025 | January 30, 2026 | January 31, 2025 | ||||||||||||
| (in millions) | |||||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income | $ | 85 | $ | 98 | $ | 358 | $ | 362 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 40 | 36 | 149 | 140 | |||||||||||
| Deferred income taxes | (20 | ) | 12 | 81 | (3 | ) | |||||||||
| Stock-based compensation expense | 13 | 15 | 64 | 53 | |||||||||||
| Other | 5 | 2 | 1 | (7 | ) | ||||||||||
| Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of the acquisitions and divestitures: | |||||||||||||||
| Receivables | 192 | 22 | 161 | (86 | ) | ||||||||||
| Prepaid expenses and other current assets | 24 | (7 | ) | (44 | ) | 24 | |||||||||
| Accounts payable and other accrued liabilities | (79 | ) | (71 | ) | (101 | ) | 48 | ||||||||
| Accrued payroll and employee benefits | 8 | 28 | (28 | ) | (31 | ) | |||||||||
| Operating lease assets and liabilities, net | 3 | 1 | (2 | ) | (6 | ) | |||||||||
| Other assets and other long-term liabilities, net | (13 | ) | (21 | ) | (30 | ) | — | ||||||||
| Net cash provided by operating activities | 258 | 115 | 609 | 494 | |||||||||||
| Cash flows from investing activities: | |||||||||||||||
| Cash paid for acquisition, net of cash acquired | — | — | (203 | ) | — | ||||||||||
| Expenditures for property, plant, and equipment | (8 | ) | (15 | ) | (32 | ) | (36 | ) | |||||||
| Contributions to investments | (1 | ) | (4 | ) | (11 | ) | (7 | ) | |||||||
| Purchases of marketable securities | (4 | ) | (3 | ) | (9 | ) | (14 | ) | |||||||
| Sales of marketable securities | 2 | 2 | 7 | 12 | |||||||||||
| Proceeds from sale of equity method investments | — | — | — | 10 | |||||||||||
| Net cash used in investing activities | (11 | ) | (20 | ) | (248 | ) | (35 | ) | |||||||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from borrowings | — | 385 | 2,745 | 1,499 | |||||||||||
| Principal payments on borrowings | (1 | ) | (325 | ) | (2,474 | ) | (1,381 | ) | |||||||
| Stock repurchased and retired or withheld for taxes on equity awards | (98 | ) | (133 | ) | (445 | ) | (558 | ) | |||||||
| Dividend payments to stockholders | (17 | ) | (18 | ) | (70 | ) | (75 | ) | |||||||
| Issuances of stock | 6 | 6 | 22 | 20 | |||||||||||
| Debt issuance costs | — | — | (9 | ) | — | ||||||||||
| Other | — | — | (4 | ) | (3 | ) | |||||||||
| Net cash used in financing activities | (110 | ) | (85 | ) | (235 | ) | (498 | ) | |||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 137 | 10 | 126 | (39 | ) | ||||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 53 | 54 | 64 | 103 | |||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 190 | $ | 64 | $ | 190 | $ | 64 | |||||||
Schedule 4:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION SEGMENT OPERATING RESULTS (Unaudited) | |||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||
| January 30, 2026 | January 31, 2025 | January 30, 2026 | January 31, 2025 | ||||||||||||
| (dollars in millions) | |||||||||||||||
| Revenues | |||||||||||||||
| Defense and Intelligence | $ | 1,335 | $ | 1,360 | $ | 5,581 | $ | 5,726 | |||||||
| Civilian | 415 | 478 | 1,681 | 1,753 | |||||||||||
| Total revenues | $ | 1,750 | $ | 1,838 | $ | 7,262 | $ | 7,479 | |||||||
| Adjusted operating income (loss) | |||||||||||||||
| Defense and Intelligence | $ | 121 | $ | 113 | $ | 478 | $ | 509 | |||||||
| Civilian | 60 | 75 | 228 | 216 | |||||||||||
| Corporate | (2 | ) | (12 | ) | (4 | ) | (20 | ) | |||||||
| Total adjusted operating income | $ | 179 | $ | 176 | $ | 702 | $ | 705 | |||||||
| Adjusted operating margin | |||||||||||||||
| Defense and Intelligence | 9.1 | % | 8.3 | % | 8.6 | % | 8.9 | % | |||||||
| Civilian | 14.5 | % | 15.7 | % | 13.6 | % | 12.3 | % | |||||||
| Total adjusted operating margin | 10.2 | % | 9.6 | % | 9.7 | % | 9.4 | % | |||||||
Defense and Intelligence Results
Revenues in the fourth quarter decreased
Revenues in the fiscal year decreased
Adjusted operating income as a percentage of revenues in the fourth quarter increased compared to the same period in the prior year primarily due to timing and volume mix in the contract portfolio.
Adjusted operating income as a percentage of revenues in the fiscal year decreased from the prior year primarily due to contract completions and ramp down in volume on existing contracts and the favorable resolution of the AAV contract termination in the prior year (
Civilian Results
Revenues in the fourth quarter decreased
Revenues in the fiscal year decreased
Adjusted operating income as a percentage of revenues in the fourth quarter decreased compared to the same period in the prior year primarily due to timing and volume mix in the contract portfolio.
Adjusted operating income as a percentage of revenues in the fiscal year increased compared to the prior year primarily due to improved profitability across the contract portfolio.
Corporate Results
Adjusted operating loss in the fourth quarter decreased
Adjusted operating loss in the fiscal year decreased
Schedule 5:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
BACKLOG
(Unaudited)
The estimated value of our total backlog as of the dates presented was:
| January 30, 2026 | January 31, 2025 | ||||||||||||
| Defense and Intelligence | Civilian | Total SAIC | Defense and Intelligence | Civilian | Total SAIC | ||||||||
| (in millions) | |||||||||||||
| Funded backlog | $ | 2,511 | $ | 1,061 | $ | 3,572 | $ | 2,599 | $ | 845 | $ | 3,444 | |
| Negotiated unfunded backlog | 15,869 | 3,181 | 19,050 | 15,341 | 3,072 | 18,413 | |||||||
| Total backlog | $ | 18,380 | $ | 4,242 | $ | 22,622 | $ | 17,940 | $ | 3,917 | $ | 21,857 | |
Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts and task orders as work is performed and excludes contract awards which have been protested by competitors until the protest is resolved in our favor. SAIC segregates backlog into two categories, funded backlog and negotiated unfunded backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government agencies represents the estimated value of contracts which may cover multiple future years under which SAIC is obligated to perform, less revenues previously recognized on these contracts. Negotiated unfunded backlog represents the estimated future revenues to be earned from negotiated contracts for which funding has not been appropriated or authorized, and unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under indefinite delivery, indefinite quantity (IDIQ), U.S. General Services Administration (GSA) schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.
Schedule 6:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
This schedule describes the consolidated non-GAAP financial measures included in this earnings release. While we believe that these non-GAAP financial measures may be useful in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.
Adjusted Operating Income
| Three Months Ended | Year Ended | ||||||||||||||
| January 30, 2026 | January 31, 2025 | January 30, 2026 | January 31, 2025 | ||||||||||||
| (dollars in millions) | |||||||||||||||
| Revenues | $ | 1,750 | $ | 1,838 | $ | 7,262 | $ | 7,479 | |||||||
| Operating income | $ | 133 | $ | 138 | $ | 521 | $ | 563 | |||||||
| Operating income as a percentage of revenues | 7.6 | % | 7.5 | % | 7.2 | % | 7.5 | % | |||||||
| Depreciation of property, plant, and equipment | 8 | 8 | 30 | 25 | |||||||||||
| Amortization of intangible assets | 32 | 28 | 119 | 115 | |||||||||||
| Acquisition, integration, restructuring and impairment costs | 11 | 4 | 16 | 6 | |||||||||||
| Depreciation included in restructuring and impairment costs | (1 | ) | (1 | ) | (1 | ) | (1 | ) | |||||||
| Recovery of acquisition, integration, restructuring and impairment costs | (4 | ) | (1 | ) | (6 | ) | (3 | ) | |||||||
| Executive transition costs, net of recoveries | — | — | 16 | — | |||||||||||
| Costs related to the settlement of federal tax audits | — | — | 7 | — | |||||||||||
| Adjusted operating income(1) | $ | 179 | $ | 176 | $ | 702 | $ | 705 | |||||||
| Adjusted operating income as a percentage of revenues | 10.2 | % | 9.6 | % | 9.7 | % | 9.4 | % | |||||||
Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Depreciation of property, plant, and equipment relates to property, plant, and equipment specifically identifiable for each segment and Corporate. Adjusted operating income also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, and therefore consider acquisitions to be a non-recurring activity, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. We believe that adjusted operating income provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
EBITDA and Adjusted EBITDA
| Three Months Ended | Year Ended | ||||||||||||||
| January 30, 2026 | January 31, 2025 | January 30, 2026 | January 31, 2025 | ||||||||||||
| (dollars in millions) | |||||||||||||||
| Revenues | $ | 1,750 | $ | 1,838 | $ | 7,262 | $ | 7,479 | |||||||
| Net income | $ | 85 | $ | 98 | $ | 358 | $ | 362 | |||||||
| Interest expense, net and loss on sale of receivables | 36 | 32 | 140 | 140 | |||||||||||
| Provision for income taxes | 14 | 9 | 29 | 66 | |||||||||||
| Depreciation and amortization | 40 | 36 | 149 | 140 | |||||||||||
| EBITDA(1) | 175 | 175 | 676 | 708 | |||||||||||
| EBITDA as a percentage of revenues | 10.0 | % | 9.5 | % | 9.3 | % | 9.5 | % | |||||||
| Acquisition, integration, restructuring and impairment costs | 11 | 4 | 16 | 6 | |||||||||||
| Depreciation included in restructuring and impairment costs | (1 | ) | (1 | ) | (1 | ) | (1 | ) | |||||||
| Recovery of acquisition, integration, restructuring and impairment costs | (4 | ) | (1 | ) | (6 | ) | (3 | ) | |||||||
| Executive transition costs, net of recoveries | — | — | 16 | — | |||||||||||
| Costs related to the settlement of federal tax audits | — | — | 7 | — | |||||||||||
| Adjusted EBITDA(1) | $ | 181 | $ | 177 | $ | 708 | $ | 710 | |||||||
| Adjusted EBITDA as a percentage of revenues | 10.3 | % | 9.6 | % | 9.7 | % | 9.5 | % | |||||||
The performance measure EBITDA is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition, integration, restructuring and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. We believe that EBITDA and adjusted EBITDA provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of our Company.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Diluted Earnings Per Share
| Three Months Ended January 30, 2026 | |||||||||||||||||||
| As Reported | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Non-GAAP results(1) | |||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||
| Income before income taxes | $ | 99 | $ | 32 | $ | 11 | $ | (4 | ) | $ | 138 | ||||||||
| Income tax expense | (14 | ) | (5 | ) | (1 | ) | 1 | (19 | ) | ||||||||||
| Net income | $ | 85 | $ | 27 | $ | 10 | $ | (3 | ) | $ | 119 | ||||||||
| Diluted EPS | $ | 1.87 | $ | 0.60 | $ | 0.22 | $ | (0.07 | ) | $ | 2.62 | ||||||||
| Three Months Ended January 31, 2025 | |||||||||||||||||||
| As Reported | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Non-GAAP results(1) | |||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||
| Income before income taxes | $ | 107 | $ | 28 | $ | 4 | $ | (1 | ) | $ | 138 | ||||||||
| Income tax expense | (9 | ) | (2 | ) | (1 | ) | — | (12 | ) | ||||||||||
| Net Income | $ | 98 | $ | 26 | $ | 3 | $ | (1 | ) | $ | 126 | ||||||||
| Diluted EPS | $ | 2.00 | $ | 0.53 | $ | 0.06 | $ | (0.02 | ) | $ | 2.57 | ||||||||
Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. Adjusted diluted earnings per share is calculated by taking diluted earnings per share and excluding amortization of intangible assets, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. We believe that adjusted diluted earnings per share provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Diluted Earnings Per Share
| Year Ended January 30, 2026 | |||||||||||||||||||||||||
| As Reported | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Executive transition costs, net of recoveries | Costs related to the settlement of federal tax audits | Non-GAAP results(1) | |||||||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||||||||
| Income before income taxes | $ | 387 | $ | 119 | $ | 16 | $ | (6 | ) | $ | 16 | $ | 7 | $ | 539 | ||||||||||
| Income tax expense | (29 | ) | (10 | ) | (1 | ) | 1 | — | — | (39 | ) | ||||||||||||||
| Net income | $ | 358 | $ | 109 | $ | 15 | $ | (5 | ) | $ | 16 | $ | 7 | $ | 500 | ||||||||||
| Diluted EPS | $ | 7.70 | $ | 2.34 | $ | 0.33 | $ | (0.11 | ) | $ | 0.34 | $ | 0.15 | $ | 10.75 | ||||||||||
| Year Ended January 31, 2025 | |||||||||||||||||||
| As Reported | Amortization of intangible assets | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Non-GAAP results(1) | |||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||
| Income before income taxes | $ | 428 | $ | 115 | $ | 6 | $ | (3 | ) | $ | 546 | ||||||||
| Income tax expense | (66 | ) | (18 | ) | (1 | ) | — | (85 | ) | ||||||||||
| Net Income | $ | 362 | $ | 97 | $ | 5 | $ | (3 | ) | $ | 461 | ||||||||
| Diluted EPS | $ | 7.17 | $ | 1.92 | $ | 0.10 | $ | (0.06 | ) | $ | 9.13 | ||||||||
Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. Adjusted diluted earnings per share is calculated by taking diluted earnings per share and excluding amortization of intangible assets, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. We believe that adjusted diluted earnings per share provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Free Cash Flow
| Three Months Ended | Year Ended | ||||||||||||||
| January 30, 2026 | January 31, 2025 | January 30, 2026 | January 31, 2025 | ||||||||||||
| (in millions) | |||||||||||||||
| Net cash provided by operating activities | $ | 258 | $ | 115 | $ | 609 | $ | 494 | |||||||
| Expenditures for property, plant, and equipment | (8 | ) | (15 | ) | (32 | ) | (36 | ) | |||||||
| Cash used from (provided by) MARPA Facility | 86 | 136 | — | 41 | |||||||||||
| Free cash flow(1) | $ | 336 | $ | 236 | $ | 577 | $ | 499 | |||||||
| FY27 Guidance | |
| (in millions) | |
| Net cash provided by operating activities | > |
| Expenditures for property, plant, and equipment | Approximately |
| Free cash flow(1) | > |
Free cash flow is calculated by taking cash flows provided by operating activities less expenditures for property, plant, and equipment and less cash flows from our Master Accounts Receivable Purchasing Agreement (MARPA Facility) for the sale of certain designated eligible U.S. government receivables. Under the MARPA Facility, the Company can sell eligible receivables up to a maximum amount of
(1)Non-GAAP measure, see above for definition.
FAQ
What were SAIC's key Q4 FY26 financial results (SAIC)?
How did SAIC perform for full fiscal year 2026 (SAIC)?
What guidance did SAIC give for fiscal year 2027 (SAIC)?
What did SAIC report about cash flow and capital deployment in FY26 (SAIC)?
What backlog and bookings figures did SAIC disclose for FY26 (SAIC)?